Safety and efficacy of peramivir for influenza treatment

References

• Glezen WP Clinical practice. Prevention and treatment of seasonal influenza N Engl J Med 2008 359 24 2579 2585 19073977
   PubMed Web of Science ®Google Scholar
• Fiore AE Fry A Shay D Gubareva L Bresee JS Uyeki TM Centers for Disease Control and Prevention (CDC) Antiviral agents for the treatment and chemoprophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 2011 60 1 1 24 21248682
   PubMedGoogle Scholar
• Bouvier NM Palese P The biology of influenza viruses Vaccine 2008 26 D49 D53 19230160
   PubMed Web of Science ®Google Scholar
• Gubareva LV Kaiser L Hayden FG Influenza virus neuraminidase inhibitors Lancet 2000 355 9206 827 835 10711940
   PubMed Web of Science ®Google Scholar
• Bright RA Medina MJ Xu X Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern Lancet 2005 366 9492 1175 1181 16198766
   PubMed Web of Science ®Google Scholar
• Bantia S Parker CD Ananth SL Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir Antimicrob Agents Chemother 2001 45 4 1162 1167 11257030
   PubMed Web of Science ®Google Scholar
• Bantia S Arnold CS Parker CD Upshaw R Chand P Anti-influenza virus activity of peramivir in mice with single intramuscular injection Antiviral Res 2006 69 1 39 45 16325932
   PubMed Web of Science ®Google Scholar
• Bautista E Chotpitayasunondh T Gao Z Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection N Engl J Med 2010 362 18 1708 1719 20445182
   PubMed Web of Science ®Google Scholar
• BioCryst Pharmaceuticals. [homepage on the Internet] Birmingham:Corporate Partnerships Available from: http://www.biocryst.com/peramivir Accessed September 4, 2014
   Google Scholar
• Fever lasting for less than 34 hours in patients treated with peramivir [pamphlet] Osaka Shionogi & Co., Ltd 2013
   Google Scholar
• Kohno S Yen MY Cheong HJ S-021812 Clinical Study Group Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection Antimicrob Agents Chemother 2011 55 11 5267 5276 21825298
   PubMed Web of Science ®Google Scholar
• Sugaya N Kohno S Ishibashi T Wajima T Takahashi T Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection Antimicrob Agents Chemother 2012 56 1 369 377 22024821
   PubMed Web of Science ®Google Scholar
• BioCryst Pharmaceuticals. [homepage on the Internet] Birmingham BioCryst’s Partner Green Cross Receives Marketing & Manufacturing Approval for Peramivir in South Korea Available from: http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=499386 Accessed September 4, 2014
   Google Scholar
• Birnkrant D Cox E The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza N Engl J Med 2009 361 23 2204 2207 19884645
   PubMed Web of Science ®Google Scholar
• Jefferson T Jones MA Doshi P Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children Cochrane Database Syst Rev 2014 4 CD008965 24718923
   PubMed Web of Science ®Google Scholar
• Drusano GL Treanor J Fowler C RWJ-270201 rapidly clears both influenza A and B in challenge studies III International Symposium on Respiratory Viral Infections 12 1 2000 St.Lucia
   Google Scholar
• Young D Fowler C Bush K RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza Philos Trans R Soc Lond B Biol Sci 2001 356 1416 1905 1913 11779391
   PubMed Web of Science ®Google Scholar
• Hayden FG Treanor JJ Qu R Fowler C Safety and efficacy of an oral neuraminidase inhibitor RWJ-270201 in treating experimental influenza A and B in healthy adult volunteers Poster presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17–20, 2000 Toronto, Ontario Abstract
   Google Scholar
• Sidwell RW Smee DF Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza Expert Opin Investig Drugs 2002 11 6 859 869
   PubMed Web of Science ®Google Scholar
• Barroso L Treanor J Gubareva L Hayden FG Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment Antivir Ther 2005 10 8 901 910 16430195
   PubMed Web of Science ®Google Scholar
• Castillo R Holland LE Boltz DA Peramivir and its use in H1N1 influenza Drugs Today (Barc) 2010 46 6 399 408 20571608
   PubMed Web of Science ®Google Scholar
• Shetty AK Peek LA Peramivir for the treatment of influenza Expert Rev Anti Infect Ther 2012 10 2 123 143 22339187
   PubMed Web of Science ®Google Scholar
• Kohno S Kida H Mizuguchi M Shimada J S-021812 Clinical Study Group Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection Antimicrob Agents Chemother 2010 54 11 4568 4574 20713668
   PubMed Web of Science ®Google Scholar
• Ison MG Fraiz J Heller B Intravenous peramivir for treatment of influenza in hospitalized patients Antivir Ther Epub 8 28 2013
   Web of Science ®Google Scholar
• Kohno S Kida H Mizuguchi M S-021812 Clinical Study Group Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients Antimicrob Agents Chemother 2011 55 6 2803 2812 21464252
   PubMed Web of Science ®Google Scholar
• Ison MG Hui DS Clezy K A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults Antivir Ther 2013 18 5 651 661 23111657
   PubMed Web of Science ®Google Scholar
• Bennett R [webpage on the Internet] BioCryst announces outcome from the peramivir Phase 3 interim analysis Durham, NC BioCryst Pharmaceuticals, Inc 2012 Available from: http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=719562 Accessed November 7, 2012
   Google Scholar
• Smith SM Gums JG Antivirals for influenza: strategies for use in pediatrics Paediatr Drugs 2010 12 5 285 299 20799758
   PubMedGoogle Scholar
• Mancuso CE Gabay MP Steinke LM Vanosdol SJ Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza Ann Pharmacother 2010 44 7–8 1240 1249 20516360
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. [homepage on the Internet] Atlanta Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season [updated 2009 December 7] Available from: http://www.cdc.gov/h1n1flu/recommendations.htm Accessed September 4, 2014
   Google Scholar
• Shrestha SS Swerdlow DL Borse RH Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (Apr 2009–Apr 2010) Clin Infect Dis 2011 52 Suppl 1 S75 S82 21342903
   PubMed Web of Science ®Google Scholar
• Yu Y Garg S Yu PA Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, Oct 2009–Jun 2010 Clin Infect Dis 2012 55 1 8 15 22491506
   PubMed Web of Science ®Google Scholar
• Doshi S Kamimoto L Finelli L Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005–2009 J Infect Dis 2011 204 12 1848 1856 22013219
   PubMed Web of Science ®Google Scholar
• Fry AM Pérez A Finelli L Use of intravenous neuraminidase inhibitors during the 2009 pandemic: results from population-based surveillance JAMA 2011 306 2 160 162 21750292
   PubMed Web of Science ®Google Scholar
• Hernandez JE Adiga R Armstrong R eIND Peramivir Investigators Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States Clin Infect Dis 2011 52 6 695 706 21367722
   PubMed Web of Science ®Google Scholar
• Jain S Fry AM Peramivir: another tool for influenza treatment? Clin Infect Dis 2011 52 6 707 709 21367723
   PubMed Web of Science ®Google Scholar
• Louie JK Yang S Yen C Acosta M Schechter R Uyeki TM Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09 PLoS One 2012 7 6 e40261 22768265
   PubMed Web of Science ®Google Scholar
• Sorbello A Jones SC Carter W Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus Clin Infect Dis 2012 55 1 1 7 22491501
   PubMed Web of Science ®Google Scholar
• Randolph AG Vaughn F Sullivan R Pediatric Acute Lung Injury and Sepsis Investigator’s Network and the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network Critically ill children during the 2009–2010 influenza pandemic in the United States Pediatrics 2011 128 6 e1450 e1458 22065262
   PubMed Web of Science ®Google Scholar
• Jouvet P Hutchison J Pinto R Critical illness in children with influenza A/pH1N1 2009 infection in Canada Pediatr Crit Care Med 2010 11 5 603 609 20308929
   PubMed Web of Science ®Google Scholar
• The ANZIC Influenza Investigators Critical care services and 2009 H1N1 influenza in Australia and New Zealand N Engl J Med 2009 361 20 1925 1934 19815860
   PubMed Web of Science ®Google Scholar
• Farias JA Fernandez A Monteverde E Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina Intensive Care Med 2010 36 6 1015 1022 20237757
   PubMed Web of Science ®Google Scholar
• Louie JK Yang S Samuel MC Uyeki TM Schechter R Neuraminidase inhibitors for critically ill children with influenza Pediatrics 2013 132 6 e1539 e1545 24276847
   PubMed Web of Science ®Google Scholar
• Treanor JJ Hayden FG Vrooman PS Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group JAMA 2000 283 8 1016 1024 10697061
   PubMed Web of Science ®Google Scholar
• Urushihara H Matsui S Kawakami K Emergency authorization of medical products: regulatory challenges from the 2009 H1N1 influenza pandemic in Japan Biosecur Bioterror 2012 10 4 372 382 23210832
   PubMedGoogle Scholar
• Tominaga T Ando Y Nagai N Sato J Kondo T Balancing societal needs and regulatory certainty: the case study of peramivir in Japan Clin Pharmacol Ther 2013 93 4 342 344 23422872
   PubMed Web of Science ®Google Scholar
• Takemoto Y Asai T Ikezoe I Clinical Effects of Oseltamivir, Zanamivir, Laninamivir and Peramivir on Seasonal Influenza Infection in Outpatients in Japan during the Winter of 2012–2013 Chemotherapy 2013 59 5 373 378 24821568
   PubMed Web of Science ®Google Scholar
• Shobugawa Y Saito R Sato I Clinical effectiveness of neuraminidase inhibitors – oseltamivir, zanamivir, laninamivir, and peramivir – for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan J Infect Chemother 2012 18 6 858 864 22644080
   PubMed Web of Science ®Google Scholar
• Hikita T Hikita H Hikita F Hikita N Hikita S Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients Int J Pediatr 2012 2012 834181 22518184
   PubMedGoogle Scholar
• Yoshino Y Seo K Koga I Kitazawa T Ota Y Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan Clin Respir J Epub 3 10 2014
   Web of Science ®Google Scholar
• Donner B Bader-Weder S Schwarz R Peng MM Smith JR Niranjan V Safety profile of oseltamivir during the 2009 influenza pandemic Pharmacoepidemiol Drug Saf 2011 20 5 532 543 21448900
   PubMed Web of Science ®Google Scholar
• Michiels B Van Puyenbroeck K Verhoeven V Vermeire E Coenen S The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews PLoS One 2013 8 4 e60348 23565231
   PubMed Web of Science ®Google Scholar
• Burch J Paulden M Conti S Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation Health Technol Assess 2009 13 58 1 265 iii iv 19954682
   PubMed Web of Science ®Google Scholar
• Relenza dear doctor letter in EU follows US advisory “The Pink Sheet” F-D-C Reports Chevy Chase, MD 2000
   Google Scholar
• Williamson JC Pegram PS Respiratory distress associated with zanamivir N Engl J Med 2000 342 9 661 662 10702061
   PubMed Web of Science ®Google Scholar
• Wang K Shun-Shin M Gill P Neuraminidase inhibitors for preventing and treating influenza in children Cochrane Database Syst Rev 2012 1 CD002744 22258949
   PubMed Web of Science ®Google Scholar
• Okumura A Kubota T Kato T Morishima T Oseltamivir and delirious behavior in children with influenza Pediatr Infect Dis J 2006 25 6 572 16732168
   PubMed Web of Science ®Google Scholar
• Toovey S Rayner C Prinssen E Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review Drug Saf 2008 31 12 1097 1114 19026027
   PubMed Web of Science ®Google Scholar
• Hama R Oseltamivir’s adverse reactions: fifty sudden deaths may be related to central suppression BMJ 2007 335 7610 59 17626921
   PubMed Web of Science ®Google Scholar
• TAMIFLU^® (oseltamivir phosphate) [prescribing information] South San Francisco, CA Genentech, Inc 2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021087s057lbl.pdf Accessed September 4, 2014
   Google Scholar
• Shin JH Kim BY Park HR Kim SW Kim SW The effect of pneumococcal polysaccharide vaccine in a mouse model of allergic rhinitis Otolaryngol Head Neck Surg 2013 148 3 383 390 23314157
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration Emergency Use Authorization of Peramivir IV Fact Sheet for Health Care Providers White Oak, MD United States Food and Drug Administration 2009 Available from: Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInormationforPatientsandProviders/UCM187811.pdf
   Google Scholar
• McKimm-Breschkin JL Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance Influenza Other Respir Viruses 2013 7 Suppl 1 25 36 23279894
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. [webpage on the Internet] Influenza antiviral drug resistance: questions and answers Atlanta, GA 2014 Available from: http://www.cdc.gov/flu/about/qa/antiviralresistance.htm Accessed February 28, 2014
   Google Scholar
• Gubareva LV Webster RG Hayden FG Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants Antimicrob Agents Chemother 2001 45 12 3403 3408 11709315
   PubMed Web of Science ®Google Scholar
• Gubareva LV Kaiser L Matrosovich MN Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir J Infect Dis 2001 183 4 523 31 11170976
   PubMed Web of Science ®Google Scholar
• Kiso M Mitamura K Sakai-Tagawa Y Resistant influenza A viruses in children treated with oseltamivir: descriptive study Lancet 2004 364 9436 759 65 15337401
   PubMed Web of Science ®Google Scholar
• Ward P Small I Smith J Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic J Antimicrob Chemother 2005 55 Suppl. 1 i5 21 15709056
   PubMed Web of Science ®Google Scholar
• Stephenson I Democratis J Lackenby A Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children Clin Infect Dis 2009 48 4 389 96 19133796
   PubMed Web of Science ®Google Scholar
• Weinstock DM Gubareva LV Zuccotti G Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient New Engl J 2003 348 9 867 8
   Web of Science ®Google Scholar
• Renaud C Kuypers J Englund JA Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1 J Clin Virol 2011 52 2 70 78 21684202
   PubMed Web of Science ®Google Scholar
• Ujike M Shimabukuro K Mochizuki K Obuchi M Kageyama T Shirakura M Oseltamivir-resistant influenza viruses A (H1N1) during 2007–2009 influenza seasons, Japan Emerg Infect Dis 2010 16 6 926 35 20507742
   PubMed Web of Science ®Google Scholar
• Hauge SH Dudman S Borgen K Lackenby A Hungnes O Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08 Emerg Infect Dis 2009 15 2 155 62 19193257
   PubMed Web of Science ®Google Scholar
• Esposito S Molteni CG Daleno C Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy Virol J 2010 7 202 20738882
   PubMed Web of Science ®Google Scholar
• Casalegno JS Bouscambert-Duchamp M Caro V Oseltamivir-resistant influenza A(H1N1) viruses in south of France, 2007/2009 Antivir Res 2010 87 2 242 8 20665943
   PubMed Web of Science ®Google Scholar
• Dharan NJ Gubareva LV Meyer JJ Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States JAMA 2009 301 10 1034 41 19255110
   PubMed Web of Science ®Google Scholar
• Memoli MJ Hrabal RJ Hassantoufighi A Eichelberger MC Taubenberger JK Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts Clin Infect Dis 2010 50 9 1252 1255 20345239
   PubMed Web of Science ®Google Scholar
• Abed Y Boivin G Yoshida R Kodama M Hernandez JE Parenteral peramivir treatment for oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses J Infect Dis 2011 204 10 1641 1642 author’s reply 1642–1643 21949045
   PubMed Web of Science ®Google Scholar
• Sleeman K Sheu TG Moore Z Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010–2011 Emerg Infect Dis 2011 17 11 2043 2046 22099093
   PubMed Web of Science ®Google Scholar
• Yen HL McKimm-Breschkin JL Choy KT Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population MBio 2013 4 4 pii: e00396-13
   Web of Science ®Google Scholar
• Takashita E Ejima M Itoh R A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, Nov to Dec 2013 Euro Surveill 2014 19 1 pii: 20666
   Google Scholar
• McKimm-Breschkin JL Williams J Barrett S Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase J Antimicrob Chemother 2013 68 10 2210 2221 23759505
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. [webpage on the Internet] Highly pathogenic avian influenza A (H5N1) virus Atlanta, GA Centers for Disease Control and Prevention 2014 Available from: http://www.cdc.gov/flu/avianflu/h5n1-virus.htm Accessed February 27, 2014
   Google Scholar
• Lopez-Martinez I Balish A Barrera-Badillo G Highly pathogenic avian influenza A(H7N3) virus in poultry workers, Mexico, 2012 Emerg Infect Dis 2013 19 9 1531 1534 23965808
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. [webpage on the Internet] Influenza A (H3N2) variant virus Atlanta, GA Centers for Disease Control and Prevention 2013 Available from: http://www.cdc.gov/flu/swineflu/h3n2v-cases.htm Accessed September 4, 2014
   Google Scholar
• Gao R Cao B Hu Y Human infection with a novel avian-origin influenza A (H7N9) virus N Engl J Med 2013 368 20 1888 1897 23577628
   PubMed Web of Science ®Google Scholar
• World Health Organization Confirmed Human Cases of Avian Influenza A(H7N9) Reported to WHO. Report 17 Data in WHO/HQ as of 08 April 2014,17:00 GMT+1 Geneva, Switzerland World Health Organization 2014 Available from: http://www.who.int/influenza/human_animal_interface/influenza_h7n9/17_ReportWebH7N9Number_20140408.pdf?ua=1 Accessed January 31, 2014
   Google Scholar
• Muthuri SG Myles PR Venkatesan S Leonardi-Bee J Nguyen-Van-Tam JS Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009–2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients J Infect Dis 2013 207 4 553 563 23204175
   PubMed Web of Science ®Google Scholar
• Nagai Y A watershed in clinical outcomes of human infections with highly pathogenic H5N1 avian influenza viruses: lessons from case-management in Egypt Rev Med Virol 2012 22 6 351 353 22996357
   PubMed Web of Science ®Google Scholar
• Uyeki TM Cox NJ Global concerns regarding novel influenza A (H7N9) virus infections N Engl J Med 2013 368 20 1862 1864 23577629
   PubMed Web of Science ®Google Scholar
• Baranovich T Burnham AJ Marathe BM The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome J Infect Dis 2014 209 9 1343 1353 24133191
   PubMed Web of Science ®Google Scholar
• Gao HN Lu HZ Cao B Clinical findings in 111 cases of influenza A (H7N9) virus infection N Engl J Med 2013 368 24 2277 2285 23697469
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. [webpage on the Internet] Interim guidance on the use of antiviral agents for the treatment of human infections with avian influenza A (H7N9) virus Atlanta, GA Centers for Disease Control and Prevention 2013 Available from: http://www.cdc.gov/flu/avianflu/h7n9-antiviral-treatment.htm Accessed September 30, 2013
   Google Scholar
• The Japanese Association for Infectious Diseases [webpage on the Internet] Interim guidance – avian influenza A(H7N9) virus infections in humans Tokyo, Japan The Japanese Association for Infectious Diseases 2013 Available from: http://www.kansensho.or.jp/influenza/1305_teigen.html Accessed May 17, 2013 Japanese
   Google Scholar
• Centers for Disease Control and Prevention [webpage on the Internet] Influenza antiviral medications: summary for clinicians (current for the 2013–2014 influenza season) Atlanta, GA Centers for Disease Control and Prevention 2013 Available from: http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm Accessed March 21, 2014
   Google Scholar
• Hu Y Lu S Song Z Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance Lancet 2013 381 9885 2273 2279 23726392
   PubMed Web of Science ®Google Scholar
• The Japanese Association for Infectious Diseases [webpage on the Internet] The Japanese Association for Infectious Diseases policy statement: recommendations for influenza antiviral treatment (revised) Tokyo, Japan 2011 Available from: http://www.kansensho.or.jp/influenza/110301soiv_teigen.html#n02 Accessed May 1, 2011 Japanese
   Google Scholar
• Hosoya M homepage on the Internet Available from : Administration of peramivir against severe influenza cases. http://www.jpeds.or.jp/uploads/files/2013_2014_influenza_3.pdf Accessed January 27, 2014
   Google Scholar
• Kitano M Itoh Y Ishigaki H Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques Antimicrob Agents Chemother 2014 58 8 4795 4803 24913156
   PubMed Web of Science ®Google Scholar
• Jain S Kamimoto L Bramley AM 2009 Pandemic influenza A (H1N1) Virus Hospitalizations Investigation Team Hospitalized patients with 2009 H1N1 influenza in the United States, Apr–Jun 2009 N Engl J Med 2009 361 20 1935 1944 19815859
   PubMed Web of Science ®Google Scholar
• Farias JA Fernández A Monteverde E Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina Intensive Care Med 2010 36 6 1015 1022 20237757
   PubMed Web of Science ®Google Scholar
• Dawood FS Jain S Finelli L Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team Emergence of a novel swine-origin influenza A (H1N1) virus in humans N Engl J Med 2009 360 25 2605 2615 19423869
   PubMed Web of Science ®Google Scholar
• Yu H Liao Q Yuan Y Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China BMJ 2010 341 c4779 20876641
   PubMed Web of Science ®Google Scholar
• Wong KK Jain S Blanton L Influenza-associated pediatric deaths in the United States, 2004–2012 Pediatrics 2013 132 5 796 804 24167165
   PubMed Web of Science ®Google Scholar
• Sugaya N Tamura D Yamazaki M Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children Clin Infect Dis 2008 47 3 339 345 18582202
   PubMed Web of Science ®Google Scholar
• Sugaya N Shinjoh M Mitamura K Takahashi T Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children J Infect 2011 63 4 288 294 21722665
   PubMed Web of Science ®Google Scholar
• Uyeki TM Prasad R Vukotich C Low sensitivity of rapid diagnostic test for influenza Clin Infect Dis 2009 48 9 e89 e92 19323628
   PubMed Web of Science ®Google Scholar
• Biggerstaff M Jhung M Reed C Influenza-like illness, the time to seek health-care, and influenza antiviral receipt during the 2010–2011 influenza season—United States J Infect Dis 2014 210 4 535 544 24731959
   PubMed Web of Science ®Google Scholar
• Lindegren ML Schaffner W Treatment with neuraminidase inhibitors for high-risk patients with influenza: why is adherence to antiviral treatment recommendations so low? J Infect Dis Epub 4 13 2014
   Web of Science ®Google Scholar
• Dominguez-Cherit G Lapinsky SE Macias AE Critically Ill patients with 2009 influenza A(H1N1) in Mexico JAMA 2009 302 17 1880 1887 19822626
   PubMed Web of Science ®Google Scholar
• Sugaya N Widespread use of neuraminidase inhibitors in Japan J Infect Chemother 2011 17 5 595 601 21850418
   PubMed Web of Science ®Google Scholar
• Beigel J Harman LA Collis PJ Pharmacokinetic and Safety Evaluations of Escalating Doses of Peramivir Administered Intravenously in Healthy Volunteers Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 17–20, 2007 Chicago, IL Abstract A-1408
   Google Scholar
• Collis PJ Harman LA Kilpatrick JM A Placebo-Controlled Evaluation of the Safety and Pharmacokinetics of Multiple-Dose Intravenous Administration of Peramivir to Healthy Elderly Subjects Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 17–20, 2007 Chicago, IL Abstract A-1409
   Google Scholar
• Alexander WJ Harman LA Collis PJ Nasal and Pharyngeal Concentrations of Peramivir Following Intramuscular and Intravenous Administration in Healthy Volunteers Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 17–20, 2007 Chicago, IL Abstract A-1410
   Google Scholar
• BioCryst Pharmaceuticals Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza Available from: http://clinicaltrials.gov/ct2/show/NCT00419263?term=NCT00419263&rank=1#wrapper. NLM identifier: NCT00419263 Accessed September 22, 2014
   Google Scholar
• Atiee G Tellier G Collis P Virologic Analysis of Influenza Viruses after Therapy with a Single Intramuscular (IM) Dose of the Neuraminidase Inhibitor (NAI) Peramivir (PVR) Versus Placebo (PBO) in Patients with Influenza in the Outpatient (OP) Setting Presented at: 49th Annual Meeting of the Infectious Diseases Society of America October 20–23, 2011 Boston, MA Abstract 1185
   Google Scholar
• nih.go.jp [homepage on the Internet] Tokyo National Institute of Infectious Diseases 2014 [updated June 23, 2014]. http://www.nih.go.jp/niid/ja/flu-m/flutoppage/2068-flu/flu-dr/4775-flu-dr20140623.html? Accessed June 23, 2014 Japanese
   Google Scholar
• Centers for Disease Control and Prevention [homepage on the Internet] Atlanta, GA: Situation Update Summary of Weekly FluView 2014 [updated October 10, 2014]. Available from: http://www.cdc.gov/flu/weekly/summary.htm Accessed October 14, 2014
   Google Scholar